Alvocidib
- Generic Name
- Alvocidib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20ClNO5
- CAS Number
- 146426-40-6
- Unique Ingredient Identifier
- 45AD6X575G
- Background
Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.
- Indication
Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 64
- Registration Number
- NCT00098371
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
- First Posted Date
- 2004-09-06
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00003039
- Locations
- 🇺🇸
Clinical Sciences Building, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Cancer Care Specialists of Central Illinois, S.C., Decatur, Illinois, United States
Flavopiridol in Treating Patients With Recurrent Prostate Cancer
- First Posted Date
- 2004-08-02
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00003256
- Locations
- 🇺🇸
Beckman Research Institute, City of Hope, Duarte, California, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer
- Conditions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00087282
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors
- Conditions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 73
- Registration Number
- NCT00003004
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
- Conditions
- Recurrent Ovarian Epithelial CancerStage IIIA Ovarian Epithelial CancerStage IIIB Ovarian Epithelial CancerStage IV Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity CancerStage IIIA Primary Peritoneal Cavity CancerStage IIIC Ovarian Epithelial CancerStage IIIB Primary Peritoneal Cavity CancerStage IIIC Primary Peritoneal Cavity CancerStage IV Primary Peritoneal Cavity Cancer
- Interventions
- First Posted Date
- 2004-05-17
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00083122
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma
- Conditions
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 18
- Registration Number
- NCT00005974
- Locations
- 🇨🇦
Nanaimo Cancer Clinic, Nanaimo, British Columbia, Canada
🇨🇦British Columbia Cancer Agency - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
🇨🇦BC Cancer Agency, Vancouver, British Columbia, Canada
Flavopiridol in Treating Patients With Refractory Cancer
- Conditions
- First Posted Date
- 2004-04-21
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019344
- Locations
- 🇺🇸
Medicine Branch, Bethesda, Maryland, United States
Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT00080990
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00079352
- Locations
- 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.